Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
- Conditions
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT03512548
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03499106
- Locations
- 🇺🇸
IQVIA, Overland Park, Kansas, United States
Drug-Drug Interaction (DDI) Study for TD-9855
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 41
- Registration Number
- NCT03432793
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03403439
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT03398421
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03383692
- Locations
- 🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Kobe University Hospital, Kobe, Hyogo, Japan
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT03346837
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 81
- Registration Number
- NCT03340662
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 40
- Registration Number
- NCT03301181
- Locations
- 🇺🇸
West Coast Clinical Trials (WCCT), Cypress, California, United States
A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03222310
- Locations
- 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.